Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in triple-negative breast cancer. Gloria Echeverria, Ph.D., instructor in Experimental Radiation Oncology, presents these findings today at the 2019 San Antonio Breast Cancer Symposium, which provide possible leads for improving breast cancer treatment.
Triple-negative breast cancer is extremely...
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...
November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the Great American Smokeout – a day focused on encouraging Americans to quit smoking.
Tobacco cessation and prevention have long been an area of focus and expertise for MD Anderson, and has been a critical component of the Lung Cancer Moon Shot® since its inception. The effort is part of MD Anderson’...
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...
MD Anderson researchers have identified early genomic events that may lead to malignant transformation. They’ve found that tissue adjacent...
Combining two types of immune checkpoint inhibitor fires up responses in T cells that are separate from those initiated by the two drugs individually...
The recent outbreak of lung injury and death associated with e-cigarettes and vaping has led to a renewed scrutiny of electronic nicotine...
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies...
Combining a 3D virtual cutting guide with a surgical navigation tool allowed MD Anderson surgeons to perform a complicated pelvic reconstruction...